Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (161-170 of 401) with videos related to

Pageof 41
Sort By:
Thrombosis and Haemostasis|February 15, 2018
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO StudyRobert F Storey, Diego Ardissino, Luigi Vignali, et al.
JAMA Cardiology|May 21, 2020
Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysisKevin R Bainey, Thomas Engstrøm, Pieter C Smits, et al.
Thrombosis and Haemostasis|April 22, 2016
Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarctionMark R Thomas, Allison C Morton, Rashed Hossain, et al.
European Heart Journal. Acute Cardiovascular Care|April 6, 2016
Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudyEvangelos Giannitsis, Lars Wallentin, Stefan K James, et al.
American Heart Journal|June 23, 2014
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes studyAxel Akerblom, Niclas Eriksson, Lars Wallentin, et al.
American Heart Journal|November 10, 2012
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) studyAxel Akerblom, Lars Wallentin, Agneta Siegbahn, et al.
Expert Review of Cardiovascular Therapy|July 1, 2024
Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillationMark A Sammut, Dwayne Conway, Javaid Iqbal, et al.
Journal of Thrombosis and Thrombolysis|September 13, 2019
Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAxel Åkerblom, Daniel Wojdyla, Philippe Gabriel Steg, et al.
Clinical Cardiology|August 8, 2021
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational studyEva Lesén, Christopher Hewitt, Evangelos Giannitsis, et al.
European Heart Journal. Acute Cardiovascular Care|December 24, 2019
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrelMark R Thomas, Stefan K James, Richard C Becker, et al.
Pageof 41

Showing results (161-170 of 401) with videos related to

Sort By:
Pageof 41
Thrombosis and Haemostasis|February 15, 2018
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO StudyRobert F Storey, Diego Ardissino, Luigi Vignali, et al.
JAMA Cardiology|May 21, 2020
Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysisKevin R Bainey, Thomas Engstrøm, Pieter C Smits, et al.
Thrombosis and Haemostasis|April 22, 2016
Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarctionMark R Thomas, Allison C Morton, Rashed Hossain, et al.
European Heart Journal. Acute Cardiovascular Care|April 6, 2016
Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudyEvangelos Giannitsis, Lars Wallentin, Stefan K James, et al.
American Heart Journal|June 23, 2014
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes studyAxel Akerblom, Niclas Eriksson, Lars Wallentin, et al.
American Heart Journal|November 10, 2012
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) studyAxel Akerblom, Lars Wallentin, Agneta Siegbahn, et al.
Expert Review of Cardiovascular Therapy|July 1, 2024
Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillationMark A Sammut, Dwayne Conway, Javaid Iqbal, et al.
Journal of Thrombosis and Thrombolysis|September 13, 2019
Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAxel Åkerblom, Daniel Wojdyla, Philippe Gabriel Steg, et al.
Clinical Cardiology|August 8, 2021
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational studyEva Lesén, Christopher Hewitt, Evangelos Giannitsis, et al.
European Heart Journal. Acute Cardiovascular Care|December 24, 2019
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrelMark R Thomas, Stefan K James, Richard C Becker, et al.
Pageof 41